Literature DB >> 21561741

The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis.

G Faber1, H G O M Smid, A R Van Gool, D Wiersma, R J Van Den Bosch.   

Abstract

OBJECTIVE: To assess the effects of second generation antipsychotics on neurocognitive function in patients with stable remission of first episode psychosis.
METHODS: Fifty-three patients with first onset psychosis in the schizophrenia spectrum entered a randomised controlled trial of guided discontinuation (GD) versus maintenance treatment (MT) with second generation antipsychotics. A comprehensive neurocognitive test battery was administered at the time of remission and shortly after dose reduction or discontinuation (GD-group) or at the same time in the MT-group.
RESULTS: With the exception of negative symptoms, PANSS scores decreased over time and neurocognition improved significantly on most tests in both groups. The GD-group, however, improved significantly more than the MT-group on three neurocognitive measures in the domain of speed of processing.
CONCLUSION: These data suggest that, in first episode patients, dose reduction or discontinuation of second generation antipsychotics after stable remission is achieved, might improve neurocognitive function more than continuing second generation antipsychotics, suggesting a negative role for second generation antipsychotics, specifically in the domain of speed of processing.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21561741     DOI: 10.1016/j.eurpsy.2011.02.003

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  11 in total

1.  Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★.

Authors:  Junchao Huang; Yu Zhu; Fengmei Fan; Song Chen; Yuan Hong; Yimin Cui; Xingguang Luo; Shuping Tan; Zhiren Wang; Lan Shang; Ying Yuan; Jianxin Zhang; Fude Yang; Chiang-Shan R Li; Laura M Rowland; Peter Kochunov; Fengyu Zhang; L Elliot Hong; Yunlong Tan
Journal:  Psychiatry Res Neuroimaging       Date:  2020-02-04       Impact factor: 2.376

Review 2.  The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.

Authors:  Stefan Leucht; Inge Winter-van Rossum; Stephan Heres; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Marion Leboyer; F Markus Leweke; Shôn Lewis; Phillip McGuire; Andreas Meyer-Lindenberg; Dan Rujescu; Shitij Kapur; René S Kahn; Iris E Sommer
Journal:  Schizophr Bull       Date:  2015-03-18       Impact factor: 9.306

3.  An observational study of antipsychotic medication discontinuation in first-episode psychosis: clinical and functional outcomes.

Authors:  Ashok Malla; Srividya N Iyer; Ridha Joober; Thara Rangaswamy; Padmavati Ramachandran; Norbert Schmitz; Aarati Taksal; Greeshma Mohan; Howard C Margolese
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2022-01-18       Impact factor: 4.328

4.  To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial.

Authors:  Marieke J H Begemann; Ilse A Thompson; Wim Veling; Shiral S Gangadin; Chris N W Geraets; Erna van 't Hag; Sanne J Müller-Kuperus; Priscilla P Oomen; Alban E Voppel; Mark van der Gaag; Martijn J Kikkert; Jim Van Os; H Filip E Smit; Rikus H Knegtering; Sybren Wiersma; Luyken H Stouten; Harm J Gijsman; Lex Wunderink; Anton B P Staring; Selene R T Veerman; Amrita G S Mahabir; Jörg Kurkamp; Gerdina H M Pijnenborg; Natalie D Veen; Machteld Marcelis; Koen P Grootens; Gunnar Faber; Nico J van Beveren; Agaath Been; Truus van den Brink; Maarten Bak; Therese A M J van Amelsvoort; Andrea Ruissen; Christine Blanke; Karin Groen; Lieuwe de Haan; Iris E C Sommer
Journal:  Trials       Date:  2020-02-07       Impact factor: 2.279

5.  Making decisions about antipsychotics: a qualitative study of patient experience and the development of a decision aid.

Authors:  S J Kaar; C Gobjila; E Butler; C Henderson; O D Howes
Journal:  BMC Psychiatry       Date:  2019-10-23       Impact factor: 3.630

6.  A systematic review of the effects of psychiatric medications on social cognition.

Authors:  Zoë Haime; Andrew J Watson; Nadia Crellin; Louise Marston; Eileen Joyce; Joanna Moncrieff
Journal:  BMC Psychiatry       Date:  2021-11-29       Impact factor: 3.630

7.  Tapered discontinuation vs. maintenance therapy of antipsychotic medication in patients with first-episode schizophrenia: Obstacles, findings, and lessons learned in the terminated randomized clinical trial TAILOR.

Authors:  Anne Emilie Stürup; Carsten Hjorthøj; Nikolai Albert; Signe Dolmer; Merete Birk; Bjørn H Ebdrup; Lene Falgaard Eplov; Heidi Jensen; Ditte Lammers Vernal; Helene Speyer; Ole Mors; Merete Nordentoft
Journal:  Front Psychiatry       Date:  2022-07-22       Impact factor: 5.435

8.  The relationship between TLR4/NF-κB/IL-1β signaling, cognitive impairment, and white-matter integrity in patients with stable chronic schizophrenia.

Authors:  Hongna Li; Wenjin Chen; Mengzhuang Gou; Wei Li; Jinghui Tong; Yanfang Zhou; Ting Xie; Ting Yu; Wei Feng; Yanli Li; Song Chen; Baopeng Tian; Shuping Tan; Zhiren Wang; Shujuan Pan; Na Li; Xingguang Luo; Ping Zhang; Junchao Huang; Li Tian; Chiang-Shan R Li; Yunlong Tan
Journal:  Front Psychiatry       Date:  2022-08-16       Impact factor: 5.435

Review 9.  Psychiatrization of Society: A Conceptual Framework and Call for Transdisciplinary Research.

Authors:  Timo Beeker; China Mills; Dinesh Bhugra; Sanne Te Meerman; Samuel Thoma; Martin Heinze; Sebastian von Peter
Journal:  Front Psychiatry       Date:  2021-06-04       Impact factor: 4.157

Review 10.  Dose Reduction/Discontinuation of Antipsychotic Drugs in Psychosis; Effect on Cognition and Functional Outcomes.

Authors:  Yoshie Omachi; Tomiki Sumiyoshi
Journal:  Front Psychiatry       Date:  2018-09-20       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.